Moderna Issuance Purchase of Equity Shares Trend from 2010 to 2022

MRNA
 Stock
  

USD 171.18  0.63  0.37%   

Moderna Issuance Purchase of Equity Shares is increasing over the years with very volatile fluctuation. Issuance Purchase of Equity Shares is expected to dwindle to -752,289,474. From 2010 to 2022 Moderna Issuance Purchase of Equity Shares quarterly data regression line had arithmetic mean of 89,957,887 and slope of  6,918,407. Moderna Consolidated Income is projected to increase significantly based on the last few years of reporting. The past year's Consolidated Income was at 12.2 Billion. The current year Earning Before Interest and Taxes EBIT is expected to grow to about 14.3 B, whereas Preferred Dividends Income Statement Impact is forecasted to decline to about 19.1 M.
  
Check Moderna financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moderna main balance sheet or income statement drivers, such as Direct Expenses of 2.8 B, Consolidated Income of 13.2 B or Cost of Revenue of 2.1 B, as well as many exotic indicators such as Long Term Debt to Equity of 0.0349, Calculated Tax Rate of 7.29 or PPandE Turnover of 25.92. Moderna financial statements analysis is a perfect complement when working with Moderna Valuation or Volatility modules. It can also supplement Moderna's financial leverage analysis and stock options assessment as well as various Moderna Technical models . Additionally, see the analysis of Moderna Correlation against competitors.

Moderna Quarterly Issuance Purchase of Equity Shares

(1.28 Billion)

Moderna Issuance Purchase of Equity Shares Breakdown

Showing smoothed Issuance Purchase of Equity Shares of Moderna with missing and latest data points interpolated. A component of Net Cash Flow from Financing representing the net cash inflow (outflow) from common equity changes. Includes additional capital contributions from share issuances and exercise of stock options; and outflow from share repurchases.Moderna's Issuance Purchase of Equity Shares historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moderna's overall financial position and show how it may be relating to other accounts over time.
Issuance Purchase of Equity Shares10 Years Trend
Increasing
Very volatile
   Issuance Purchase of Equity Shares   
Share
       Timeline  

Moderna Issuance Purchase of Equity Shares Regression Statistics

Arithmetic Mean 89,957,887
Geometric Mean 856,611
Coefficient Of Variation 750.99
Mean Deviation 372,851,881
Median 11,000
Standard Deviation 675,571,129
Range 2,791,289,474
R-Value 0.039882
R-Squared 0.001591
Significance 0.90
Slope 6,918,407

Moderna Issuance Purchase of Equity Shares History

2017212 K
2018564.5 M
201951 M
2020B
2021-733 M
2022-752.3 M

About Moderna Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Moderna income statement, its balance sheet, and the statement of cash flows. Moderna investors use historical funamental indicators, such as Moderna's Issuance Purchase of Equity Shares, to determine how well the company is positioned to perform in the future. Although Moderna investors may use each financial statement separately, they are all related. The changes in Moderna's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Moderna's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Moderna Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Moderna. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Issuance Purchase of Equity Shares-733 M-752.3 M
Average Equity8.7 B9.4 B
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3200 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moderna without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Alpha Finder Now

   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moderna using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Moderna Correlation against competitors. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.19
Market Capitalization
67.2 B
Quarterly Revenue Growth YOY
0.091
Return On Assets
0.46
Return On Equity
1.14
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.